Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice

Background Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated b...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianping Sun, Larry Wang, Michael John Zobel, Abigail K Zamora, Hong-wei Wu, Danny Lascano, Jemily Malvar, Michael A Sheard, Robert C Seeger, Eugene S Kim
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001560.full
Tags: Add Tag
No Tags, Be the first to tag this record!